Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. by Fitzmaurice, Christina et al.
Global, Regional, and National Cancer Incidence, Mortality, Years of Life
Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29
Cancer Groups, 1990 to 2017
A Systematic Analysis for the Global Burden of Disease Study
Global Burden of Disease Cancer Collaboration
IMPORTANCE Cancer and other noncommunicable diseases (NCDs) are now widely
recognized as a threat to global development. The latest United Nations high-level meeting
on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the
2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and
the third Sustainable Development Goal. Lack of situational analyses, priority setting, and
budgeting have been identified as major obstacles in achieving these goals. All of these have
in common that they require information on the local cancer epidemiology. The Global
Burden of Disease (GBD) study is uniquely poised to provide these crucial data.
OBJECTIVE To describe cancer burden for 29 cancer groups in 195 countries from 1990
through 2017 to provide data needed for cancer control planning.
EVIDENCE REVIEW We used the GBD study estimation methods to describe cancer incidence,
mortality, years lived with disability, years of life lost, and disability-adjusted life-years
(DALYs). Results are presented at the national level as well as by Socio-demographic Index
(SDI), a composite indicator of income, educational attainment, and total fertility rate. We
also analyzed the influence of the epidemiological vs the demographic transition on cancer
incidence.
FINDINGS In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million
without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of
cancer DALYs came from years of life lost (97%), and only 3% came from years lived with
disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and
the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident
cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL)
cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most
common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and
28.4 million DALYs), liver cancer (572 000 deaths and 15.2 million DALYs), and stomach
cancer (542 000 deaths and 12.2 million DALYs). For women in 2017, the most common
incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident
cases), and colorectal cancer (819 000 incident cases). The leading causes of cancer deaths
and DALYs for women were breast cancer (601 000 deaths and 17.4 million DALYs), TBL
cancer (596 000 deaths and 12.6 million DALYs), and colorectal cancer (414 000 deaths and
8.3 million DALYs).
CONCLUSIONS AND RELEVANCE The national epidemiological profiles of cancer burden in the
GBD study show large heterogeneities, which are a reflection of different exposures to risk
factors, economic settings, lifestyles, and access to care and screening. The GBD study can be
used by policy makers and other stakeholders to develop and improve national and local
cancer control in order to achieve the global targets and improve equity in cancer care.
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C ancer is now widely recognized as a global problem thatunfortunately lacks a global solution. The latest UnitedNations high-level meeting on noncommunicable dis-
eases (NCDs) exemplified this conundrum.1 Despite global com-
mitment to reducing the risk of and disability from NCDs, in-
cluding cancer, implementation of known solutions is
inadequate to reach the 2011 Political Declaration on the Pre-
vention and Control of Noncommunicable Diseases2,3 (25% re-
duction in premature mortality from NCDs by 2025) and the
third Sustainable Development Goal (by 2030 reduce by one-
third premature mortality from NCDs through prevention and
treatment, and promote mental health and well-being).4 To re-
duce cancer burden, identifying the scope of the problem and
mapping out implementation of solutions is best done in Na-
tional Cancer Control Plans (NCCPs). However, a recent re-
view showed that only 29% of low-income countries had a
NCCP, and even if NCCPs existed, cost, financing, monitor-
ing, and expansion of information systems was often inad-
equate. Many highly effective prevention and treatment strat-
egies exist for cancer. However, they are often very specific (eg,
vaccination for human papillomavirus and hepatitis B virus for
prevention of cervical and liver cancer, or tyrosine kinase in-
hibitors for cancers with targetable mutations). Effective NCCPs
therefore require detailed knowledge about the local burden
of cancer and associated risk factors. We herein present re-
sults from the Global Burden of Disease (GBD) 2017 study de-
scribing cancer incidence, mortality, years of life lost (YLLs),
years lived with disability (YLDs), and disability-adjusted life-
years (DALYs) for 195 countries from 1990 through 2017, which
can inform cancer control through policy, resource alloca-
tion, and health system planning.
Methods
Methods have remained similar to the GBD 2016 study.5 De-
tailed descriptions of the methods can be found in the GBD 2017
publications6-9 as well as in the eAppendix, eFigures, and
eTables in the Supplement. For each GBD study, the entire time
series is re-estimated. This study therefore supersedes prior
GBD iterations. The GBD study is compliant with the Guide-
lines for Accurate and Transparent Health Estimates Report-
ing statement (eTable 1 in the Supplement). Compared with the
prior GBD study (GBD 2016), the neoplasms category for GBD
2017 also includes benign and in situ neoplasms (Interna-
tional Statistical Classification of Diseases and Related Health
Problems, Tenth Revision [ICD-10] codes D00-D49). Because
disability associated with benign neoplasms is most often very
small, we only estimated disability for the new cause: myelo-
dysplastic, myeloproliferative, and other hematopoietic neo-
plasms. The terms malignant neoplasms or cancer in this ar-
ticle only include ICD-10 codes C00 through C96. Other
changes since GBD 2016 are the addition of new data sources
(eTable 3 in the Supplement) for GBD 2017 and improve-
ments in the way we estimated cancer survival by using the
mortality-to-incidence ratio (MIR). In this study, estimates are
presented for 29 cancer categories and 195 countries and ter-
ritories. Estimates for benign neoplasms as well as selected sub-
national estimates are available online (https://vizhub.
healthdata.org/gbd-compare/ and http://ghdx.healthdata.org/
gbd-results-tool). All rates are reported per 100 000 person-
years. The GBD world population standard was used for the
calculation of age-standardized rates.9 We report 95%
uncertainty intervals for all estimates.
Estimation Framework
The GBD cancer estimation process starts with mortality. Mor-
tality estimates are made based on vital registration system
(83% of data), cancer registry (16% of data) (eTable 3 in the
Supplement), and verbal autopsy data (1% of data) using an en-
semble model approach.9,10 Predictive covariates used in the
model can be found in the eAppendix (eTable 8 in the Supple-
ment). Single-cause mortality estimates are scaled into the
separately estimated all-cause estimate.9 To estimate cancer
incidence, mortality estimates are divided by a separately es-
timated MIR for each cancer type, sex, 5-year age group, lo-
cation, and year; additional information regarding incidence
and MIR estimation can be found in the eAppendix and eFig-
ure 2 in the Supplement. Data sources used for estimating MIRs
are described in eTable 2 in the Supplement. MIRs allow for a
uniform method to estimate incidence. Other cancer estima-
tion frameworks11,12 have set a precedent for using MIRs for
decades and have detailed its benefits, including greater rep-
resentativeness, especially in settings that lack quality or com-
plete population-based cancer registry systems. By determin-
ing incidence using mortality, we are able to account for
uncaptured incident cases and, if mortality and incidence are
determined correctly, estimating incidence based on MIRs
should result in the similar results if using incidence directly.
The correlation between survival data and the MIR is used to
estimate 10-year cancer prevalence. Total prevalence is par-
titioned into 4 sequelae: (1) diagnosis/treatment, (2) remis-
sion, (3) metastatic/disseminated, and (4) terminal phase. Each
sequela prevalence is multiplied by a disability weight to es-
timate YLDs. Lifetime prevalence of procedure-related dis-
ability is estimated for larynx, breast, colorectal, bladder, and
Key Points
Question What is the cancer burden over time at the global and
national levels, measured in incidence, mortality, years lived with
disability, years of life lost, and disability-adjusted life-years
(DALYs), and how does it compare with other diseases?
Findings Results of this systematic analysis show that in 2017
there were 24.5 million incident cases (16.8 million without
nonmelanoma skin cancer), 9.6 million deaths, and 233.5 million
DALYs due to cancer; between 2007 and 2017, incident cases
increased by 33%, with the lowest increase in the most developed
countries, and between 1990 and 2017 neoplasms increased
among the top causes of DALYs from the sixth to the second place.
Fifty-one percent of cancer cases occurred in countries of high
Socio-demographic Index, but only 30% of cancer deaths and
24% of cancer DALYs.
Meaning To ensure sustainable global development, increased
efforts are needed in cancer prevention and in ensuring universal
access to cancer care.
Research Original Investigation Global Burden of Cancer, 1990 to 2017
1750 JAMA Oncology December 2019 Volume 5, Number 12 (Reprinted) jamaoncology.com
Downloaded From: https://jamanetwork.com/ by a Universitaetsbibliothek Bielefeld User  on 10/29/2020
prostate cancers. A standard life expectancy is used to esti-
mate years of life lost (YLLs).9 DALYs are the sum of YLDs and
YLLs. To determine the contribution of population aging, popu-
lation growth, and change in age-specific rates on the change
in incident cases between 2007 and 2017, we use hypotheti-
cal demographic scenarios holding 2 of these 3 components
constant. Results are stratified by quintiles of Socio-
demographic Index (SDI), which is a composite indicator in-
cluding fertility, education, and income.7
Results
Global Incidence, Mortality, and DALYs
In 2017, there were 24.5 million (95% UI, 22.0-27.4 million) in-
cident cancer cases worldwide and 9.6 million (95% UI, 9.4-
9.7 million) cancer deaths (Table). Cancer caused 233.5 mil-
lion (95% UI, 228.8-238.0 million) DALYs in 2017, of which 97%
came from YLLs and 3% came from YLDs (eTable 15 and eFig-
ure 4 in the Supplement). Globally, the odds of developing can-
cer during a lifetime (ages 0-79 years) were 1 in 3 for men and
1 in 4 for women (eTable 16 in the Supplement). These odds
differ substantially among SDI quintiles, ranging from 1 in 7
at the lowest SDI quintile to 1 in 2 at the highest SDI quintile
for both sexes. In 2017, skin; tracheal, bronchus, and lung (TBL);
and prostate cancers were the most common incident can-
cers in men, accounting for 54% of all cancer cases. The most
common causes of cancer deaths and DALYs for men were TBL,
liver, and stomach cancers (Table). For women in 2017, the most
common incident cancers were nonmelanoma skin cancer
(NMSC), breast cancer, and colorectal cancer, accounting for
54% of all incident cases. The leading causes of cancer deaths
and DALYs for women were breast, TBL, and colorectal can-
cers.
Between 2007 and 2017, the average annual age-
standardized incidence rates (ASIRs) for all cancers com-
bined increased in 123 of 195 countries (Figure 1 and eFigure 5
in the Supplement). In contrast, the average annual age-
standardized death rates for all cancers combined decreased
within that timeframe in 145 of 195 countries (Figure 2 and eFig-
ure 6 in the Supplement). Incident cases for both sexes com-
bined increased in all SDI quintiles between 2007 and 2017 for
nearly all cancers (eTable 14 in the Supplement). The largest
increase in cancer incident cases between 2007 and 2017 oc-
curred in middle SDI countries, with a 52% increase, of which
changing age structure contributed 24%, population growth
10%, and changing age-specific incidence rates 18%. The driv-
ers behind increasing cancer incidence differ substantially by
SDI. Whereas in the lowest SDI quintile, population growth is
the major contributor to the increase in total cancer inci-
dence, in low-middle SDI countries aging and changes in in-
cidence rates contribute equally (each 12%), and in high-
middle and high SDI countries, increased incidence is mainly
driven by population aging (eTable 14 in the Supplement).
Global Top 10 Cancers in 2017
The global top 10 cancers were ranked by the highest number
of incident cases, excluding “other malignant neoplasms.”
1. Nonmelanoma Skin Cancer
In 2017, there were 7.7 million (95% UI, 5.3-10.6 million) inci-
dent cases of NMSC, of which 5.9 million (95% UI, 3.7-8.7 mil-
lion) were due to basal cell carcinoma and 1.8 million (95% UI,
1.1-2.6 million) due to squamous cell carcinoma. There were
65 000 (95% UI, 63 000-66 000) deaths due to NMSC (Table)
and 1.3 million (95% UI, 1.3-1.4 million) DALYs, of which 97%
came from YLLs (Figure 3) and 3% from YLDs (eTable 15 and
eFigure 4 in the Supplement). Over a lifetime, the odds of de-
veloping NMSC were 1 in 7 for men and 1 in 10 for women glob-
ally. For men, the odds ranged from 1 in 71 in low SDI coun-
tries to 1 in 2 in high SDI countries, and for women from 1 in
104 in low SDI countries to 1 in 4 in high SDI countries (eTable 16
in the Supplement). An aging and growing population has led
to a 33% (95% UI, 29%-36%) increase in NMSC cancer cases,
from 5.8 million (95% UI, 4.1-7.8 million) in 2007 to 7.7 mil-
lion (95% UI, 5.3-10.6 million) in 2017. The majority of this in-
crease (20%) can be attributed to a change in the population
age structure, and 13% can be attributed to population growth
(eTable 14 and eFigure 11 in the Supplement).
2. Tracheal, Bronchus, and Lung Cancer
In 2017, there were 2.2 million (95% UI, 2.1-2.2 million) inci-
dent cases of TBL cancer and 1.9 million (95% UI, 1.8-1.9 mil-
lion) deaths. Tracheal, bronchus, and lung cancer caused 40.9
million (95% UI, 40.0-41.9 million) DALYs in 2017, of which 99%
came from YLLs and 1% from YLDs (eTable 15 and eFigure 4
in the Supplement). Men were more likely to develop TBL can-
cer over a lifetime than women (1 in 17 men vs 1 in 43 women)
(eTable 16 in the Supplement). The odds were the highest in
high-middle SDI countries for men (1 in 13) and in high SDI
countries for women (1 in 28). In low SDI countries, the odds
were the lowest (1 in 45 for men and 1 in 142 for women). Tra-
cheal, bronchus, and lung cancer was the leading cause of can-
cer in high-middle SDI countries (eFigure 5 in the Supple-
ment). It was the most common cause of cancer deaths by
absolute cases globally, as well as in all SDI quintiles (eFig-
ure 6 in the Supplement). For men, TBL cancer was the most
common incident cancer in 48 countries and the most com-
mon cause for cancer deaths in 110 countries (eFigures 7 and
9 in the Supplement). For women, TBL cancer was the most
common incident cancer in Greenland and the most com-
mon cause of cancer deaths in 22 countries (eFigures 8 and 10
in the Supplement). Between 2007 and 2017, TBL cancer cases
increased by 37% (95% UI, 33%-40%). Changing age struc-
ture contributed 19%, population growth 13%, and changes in
age-specific incidence rates 5% (eTable 14 and eFigure 11 in the
Supplement). The ASIRs between 1990 and 2017 show diverg-
ing results between men and women globally and in high SDI
countries, with ASIRs decreasing in men but increasing in
women (eFigure 12 in the Supplement). In high-middle SDI
countries, ASIRs remained stable for men but increased for
women, whereas rates increased for both sexes in middle SDI
countries (eFigures 13 and 14 in the Supplement).
3. Breast Cancer
Breast cancer was the third most common incident cancer over-
all with an estimated 2.0 million (95% UI, 1.9-2.0 million) in-
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cident cases in 2017. The majority occurred in women (1.9 mil-
lion [95% UI, 1.9 -2.0 million]) (Table). Breast cancer was among
the top 3 leading causes of cancer in all SDI quintiles except
for the high and high-middle SDI quintiles, where it was the
fourth most common cancer (eFigure 5 in the Supplement). It
caused 601 000 (95% UI, 579 000-630 000) deaths in women
and 11 000 (95% UI, 10 000-11 000) deaths in men, making it
the fifth leading cause of cancer deaths for both sexes com-
bined in 2017 globally (eFigure 6 in the Supplement). For
women, breast cancer was the leading cause of cancer death
in 2017 (Table). Breast cancer caused 17.7 million (95% UI, 16.9-
18.7 million) DALYs for both sexes, of which 93% came from
YLLs and 7% from YLDs (eTable 15 and eFigure 4 in the Supple-
ment). Globally, 1 in 18 women developed breast cancer over
a lifetime (eTable 16 in the Supplement). For women, the odds
of developing breast cancer were the highest in high SDI coun-
tries (1 in 11), and the lowest in low SDI countries (1 in 38). For
women, breast cancer was the most common cancer in 143
countries and the most common cause of cancer deaths in 112
countries (eFigures 8 and 10 in the Supplement). Overall, in-
cident cases increased by 35% (95% UI, 30%-39%) because of
a change in the population age structure (contributing 15%),
population growth (contributing 13%), and an increase in age-
specific incidence rates (contributing 7%) (eFigure 11 in the
Supplement). Between 2007 and 2017, ASIRs for women de-
creased in high SDI countries but increased in the other SDI
quintiles (eFigures 12-16 in the Supplement).
4. Colon and Rectum Cancer
In 2017, there were 1.8 million (95% UI, 1.8-1.9 million) inci-
dent cases of colon and rectum cancer, and 896 000 (95% UI,
876 000-916 000) deaths (Table). Colon and rectum cancer
caused 19.0 million (95% UI, 18.5-19.5 million) DALYs in 2017,
of which 95% came from YLLs and 5% from YLDs (eTable 15
and eFigure 4 in the Supplement). The odds of developing co-
lon and rectum cancer globally were higher for men than for
women (1 in 26 for men vs 1 in 40 for women) (eTable 16 in the
Supplement). The highest odds were in the high SDI quintile
(1 in 15 for men and 1 in 25 for women) and the lowest in the
low SDI quintile (1 in 81 for men and 1 in 98 for women). Be-
tween 2007 and 2017, incidence increased by 38% (95% UI,
34%-41%), from 1.3 million (95% UI, 1.3-1.3 million) to 1.8 mil-
lion (95% UI, 1.8-1.9 million) cases (eTable 14 in the Supple-
ment). Most of this increase can be explained by an aging and
growing population (20% and 13%, respectively); however,
even with the same population size and age structure, colo-
rectal cancer cases would have increased by 5% between 2007
and 2017 owing to changing age-specific incidence rates. The
ASIRs between 1990 and 2017 are similar for men and women
Figure 1. Average Annual Percentage Change in Age-Standardized Incidence Rate in Both Sexes for All Cancers From 2007 to 2017
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at the global level and for all SDI quintiles (eFigures 12-16 in
the Supplement).
5. Prostate Cancer
In 2017, there were 1.3 million (95% UI, 1.2-1.7 million) inci-
dent cases of prostate cancer and 416 000 (95% UI, 357 000-
490 000) deaths. Prostate cancer caused 7.1 million (95% UI,
6.1 million-8.4 million) DALYs globally in 2017, with 88% com-
ing from YLLs and 12% from YLDs (eTable 15 and eFigure 4 in
the Supplement). Globally, the odds of developing prostate can-
cer were 1 in 18, ranging from 1 in 52 for low SDI countries to 1
in 9 in high SDI countries (eTable 16 in the Supplement). In 2017,
prostate cancer was the cancer with the highest incidence for
men in 114 countries and the leading cause of cancer-related
deaths for men in 56 countries (eFigures 7 and 9 in the Supple-
ment). The increasing incidence rates, together with an aging
and growing population, have led to a 42% (95% UI, 37%-
52%) increase in prostate cancer cases since 2007 (940 000
[95% UI, 774 000-1.2 million] in 2007 and 1.3 million [95% UI,
1.2-1.7 million] in 2017). Twenty-one percent of this increase
can be attributed to a change in the population age structure,
13% to a change in the population size, and 8% to a change in
the age-specific incidence rates (eTable 14 and eFigure 11 in the
Supplement).
6. Stomach Cancer
In 2017, there were 1.2 million (95% UI, 1.2-1.3 million) inci-
dent cases of stomach cancer and 865 000 (95% UI, 848 000-
885 000) deaths worldwide. Stomach cancer caused 19.1 mil-
lion (95% UI, 18.7-19.6 million) DALYs in 2017, with 98% coming
from YLLs and 2% coming from YLDs (eTable 15 and eFig-
ure 4 in the Supplement). One in 33 men and 1 in 78 women
developed stomach cancer over a lifetime. The highest odds
for men and women were in high-middle SDI countries (1 in
21 and 1 in 57, respectively), and the lowest odds were for men
in low SDI countries (1 in 78) and for women in low-middle SDI
countries (1 in 104) (eTable 16 in the Supplement). Between
2007 and 2017, stomach cancer moved from the second lead-
ing cause of crude cancer YLLs to the third place with a 5% (95%
UI, 2%-7%) increase in absolute YLLs (Figure 3). Overall, inci-
dence between 2007 and 2017 increased by 25% (95% UI, 22%-
29%), of which a change in the population age structure con-
tributed 19%, population growth 13%, and falling age-
specific rates −6% (eTable 14 and eFigure 11 in the Supplement).
The ASIRs have dropped substantially since 1990 globally and
for all SDI quintiles (eFigures 12-16 in the Supplement).
Figure 2. Average Annual Percentage Change in Age-Standardized Mortality Rate in Both Sexes for All Cancers From 2007 to 2017
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7. Liver Cancer
In 2017, there were 953 000 (95% UI, 917 000-997 000) inci-
dent cases of liver cancer globally and 819 000 (95% UI,
790 000-856 000) deaths. Liver cancer caused 20.8 million
(95% UI, 19.9-21.8 million) DALYs in 2017, with 99% coming
from YLLs and 1% coming from YLDs (eTable 15 and eFigure 4
in the Supplement). Globally, liver cancer was more common
in men, with 1 in 42 men developing liver cancer compared with
1 in 118 women. The highest odds of developing liver cancer
were in high-middle SDI countries for men (1 in 31) and in
middle SDI countries for women (1 in 94), whereas the lowest
were seen in low SDI countries (1 in 98 men and 1 in 177 wom-
en) (eTable 16 in the Supplement). Population aging and popu-
lation growth were the drivers of the increase from 705 000
(95% UI, 690 000-734 000) cases in 2007 to 953 000 (95% UI,
917 000-997 000) cases in 2017 (eTable 14 and eFigure 11 in the
Supplement). Of the 35% increase in cases between 2007 and
2017, 17% was due to population aging, 13% due to popula-
tion growth, and 6% due to an increase in age-specific inci-
dence rates.
8. Cervical Cancer
In 2017, 601 000 (95% UI, 554 000-625 000) women devel-
oped cervical cancer worldwide, and it caused 260 000 (95%
UI, 241 000-269 000) deaths (Table). Cervical cancer caused
8.1 million (95% UI, 7.5-8.4 million) DALYs, with 96% coming
from YLLs and 4% from YLDs (eTable 15 and eFigure 4 in the
Supplement). Globally, 1 in 65 women developed cervical can-
cer during a lifetime (eTable 16 in the Supplement). The odds
were the highest in low SDI countries (1 in 40) and the lowest
in high SDI countries (1 in 106). In 2017, cervical cancer was
the most common incident cancer for women in 50 countries
(eFigure 8 in the Supplement) and the most common cause of
cancer deaths in 39 countries (eFigure 10 in the Supplement).
Between 2007 and 2017, incident cases increased by 19% (95%
UI, 13%-23%) globally. Population growth contributed 13% and
population aging 9%, while falling age-specific incidence rates
offset this increase by −3% (eFigure 11 and eTable 14 in the
Supplement). Deaths increased by 19% (95% UI, 13%-23%) be-
tween 2007 and 2017, and DALYs by 15% (95% UI, 10%-19%).
Figure 3. Cancers Ranked by Absolute Years of Life Lost (YLLs) Among Both Sexes Between 2007 and 2017a
Rank Cancer 2007 Cancer 2017 Rank
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Other pharynx cancer Acute lymphoid leukemia 21
Nasopharynx cancer Multiple myeloma 22
Multiple myeloma Nasopharynx cancer 23
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–16.2 (–18.6 to –13.7)
4.0 (1.5 to 6.1)
0 (–5.6 to 5.3)
–7.2 (–11.8 to –3.9)
0.2 (–5.2 to 4.3)
–3.6 (–6.2 to 1.2)
3.0 (–2.3 to 7.6)
–20.8 (–26.5 to –15.4)
1.1 (–2.2 to 4.2)
–6.8 (–9.9 to –3.5)
–6.9 (–8.9 to –4.8)
6.5 (–1.7 to 12.8)
–1.4 (–11.3 to 5.8)
–9.1 (–11.7 to –6.4)
–3.3 (–6.9 to 0)
–4.7 (–17.6 to 4.7)
0.3 (–3.3 to 3.4)
–5.0 (–8.5 to –1.3)
–11.2 (–13.7 to –8.0)
–7.2 (–9.8 to –3.8)
–17.1 (–20.1 to –13.9)
0.5 (–2.3 to 2.6)
–2.3 (–6.6 to 2.4)
–5.4 (–10.8 to –0.8)
–19.7 (–22.4 to –17.1)
–9.2 (–12.3 to –6.1)
–10.8 (–14.5 to –6.1)
Rank increased No change Rank decreased
UI indicates uncertainty interval.
a Excluding other cancer.
Research Original Investigation Global Burden of Cancer, 1990 to 2017
1756 JAMA Oncology December 2019 Volume 5, Number 12 (Reprinted) jamaoncology.com
Downloaded From: https://jamanetwork.com/ by a Universitaetsbibliothek Bielefeld User  on 10/29/2020
The ASIRs decreased globally and for all SDI quintiles (eFig-
ures 12-16 in the Supplement).
9. Non-Hodgkin Lymphoma
In 2017, there were 488 000 (95% UI, 479 000-497 000) inci-
dent cases of non-Hodgkin lymphoma and 249 000 (95% UI,
243 000-253 000) deaths. Non-Hodgkin lymphoma caused 7.0
million (95% UI, 6.8-7.2 million) DALYs in 2017, with 97% com-
ing from YLLs and 3% from YLDs (eTable 15 and eFigure 4 in
the Supplement). Globally, 1 in 108 men and 1 in 162 women
developed non-Hodgkin lymphoma over a lifetime. The high-
est odds were in high SDI countries (1 in 54 for men and 1 in
80 for women) and the lowest in low SDI countries (1 in 221
for men and 1 in 322 for women) (eTable 16 in the Supple-
ment). Globally, incident cases between 2007 and 2017 in-
creased by 39% (95% UI, 35%-42%), of which 15% was due to
changing population age structure, 13% due to population
growth, and 11% due to change in incidence rates (eTable 14
and eFigure 11 in the Supplement).
10. Bladder Cancer
In 2017, there were 474 000 (95% UI, 462 000-492 000) inci-
dent cases of bladder cancer and 197 000 (95% UI, 192 000-
206 000) deaths. Bladder cancer caused 3.6 million (95% UI,
3.5-3.8 million) DALYs in 2017, with 93% coming from YLLs and
7% from YLDs (eTable 15 and eFigure 4 in the Supplement).
Globally, 1 in 74 men and 1 in 301 women developed bladder
cancer over a lifetime. The highest odds were in high SDI coun-
tries (1 in 42 for men and 1 in 185 for women) and the lowest
in low SDI countries (1 in 198 for men and 1 in 489 for women)
(eTable 16 in the Supplement). Globally, incident cases be-
tween 2007 and 2017 increased by 32% (95% UI, 30%-35%),
of which 20% was due to changing population age structure
and 13% to population growth (eTable 14 and eFigure 11 in the
Supplement).
Cancer in Comparison to Other Diseases
Within the 22 mutually exclusive and collectively exhaustive
GBD level 2 disease categories (eTable 17 in the Supplement),
neoplasms ranked last for incidence in 1990 and 2017 (eTable 18
in the Supplement). For prevalence, neoplasms ranked last in
1990 but surpassed enteric infections in 2017. The YLDs rank-
ing for neoplasms also increased between 1990 and 2017 from
the 21st to the 19th position. Mortality due to neoplasms re-
mained at the second place between 1990 and 2017. The larg-
est increase was seen for neoplasm YLLs and DALYs, which in-
creased from the sixth place in 1990 to the second place in 2017
after cardiovascular diseases (Figure 4). The 4 causes with
higher DALYs in 1990 that had been surpassed by neoplasms
in 2017 are respiratory infections and tuberculosis, maternal
and neonatal disorders, enteric infections, and other infec-
tions.
Discussion
The GBD study results are updated on an annual basis. In this
article we focus on changes over the past decade and present
the most recent results from the GBD 2017 study using cancer
registry, vital registration, and verbal autopsy data to esti-
Figure 4. Change in the Absolute Number of Disability-Adjusted Life-Years (DALYs) Between 1990 and 2017 for
Both Sexes at the Global Level for Global Burden of Disease Level 2 Causesa
Rank Cancer 2007
Respiratory infections and tuberculosis
Maternal and neonatal diseases
Cardiovascular diseases
Enteric infections
Other infections diseases
Neoplasms
Other noncommunicable diseases
Unintentional injury
Chronic respiratory disease
Neglected tropical diseases and malaria
Nutritional deficiencies
Musculoskeletal disorders
Mental disorders
Transport injuries
Neurological disorders
Self-harm and violence
Digestive diseases
Diabetes and chronic kidney disease
Sense organ diseases
HIV/AIDS and sexually transmitted infections
Skin diseases
Substance use
1
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4
5
6
7
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16
17
18
19
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21
22
Rank 2017
Cardiovascular diseases
Neoplasms
Maternal and neonatal disease
Respiratory infections and tuberculosis
Musculoskeletal disorders
Mental disorders
Other noncommunicable diseases
Chronic respiratory disease
Neurological disorders
Unintentional injury
Diabetes and chronic kidney disease
Enteric infections
Digestive diseases
Transport injuries
Self-harm and violence
Sense organ diseases
HIV/AIDS and sexually transmitted infections
Neglected tropical diseases and malaria
Nutritional deficiency
Other infectious diseases
Substance use
Skin diseases
Rank
1
2
3
4
5
6
7
8
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Communicable, maternal, neonatal, and nutritional diseases Noncommunicable diseases Injuries
The cause neoplasms includes all
cancers as defined under
International Statistical Classification
of Diseases and Related Health
Problems, Tenth Revision (ICD-10)
causes C00 through C96, as well as
myelodysplastic, myeloproliferative,
and other hematopoietic neoplasms
(ICD-10 codes D45-D47.9).
a All diseases are grouped into 22
mutually exclusive and collectively
exhaustive causes.
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mate the burden of cancer for 195 countries and territories from
1990 through 2017.13,14 All results presented can also be found
online at https://vizhub.healthdata.org/gbd-compare/ and
http://ghdx.healthdata.org/gbd-results-tool. For this article, we
also compare cancer burden with other diseases.
The GBD 2017 results show that there are 24.5 million in-
cident cancer cases worldwide (16.8 million without NMSC)
and 9.6 million deaths, which is similar to the latest GLOBO-
CAN estimates for 2018 that estimate 17.0 million cases (with-
out NMSC) and 9.4 million deaths.15
The largest change in our estimates compared with the last
iteration of the GBD study (GBD 2016) are the incidence esti-
mates for NMSC, which have substantially increased. Despite
being the most common incident cancer in many popula-
tions, cancer registry data to inform incidence estimates are
often unreliable or nonexistent. For GBD 2017 we have there-
fore used Marketscan data for the United States, which has led
to substantially higher estimates for NMSC.16
A key strength of the GBD study is the comparative health
assessment. Our analysis shows how cancer has increased in
importance as a global health problem. Although it ranked sixth
in 1990 among the top causes for DALYs worldwide, it has risen
to the second place in 2017 behind cardiovascular diseases.
Cancer now occupies the second place in the ranking of global
deaths, YLLs, and DALYs, and is among the top 2 leading causes
of deaths, YLLs, and DALYs in the highest 3 SDI quintiles. This
shift in disease burden owing to the demographic and epide-
miological transitions has important implications on health
policy: ensuring access to universal health coverage and pro-
tection against catastrophic health expenditure directly re-
lated to the cancer treatment, but also against the long-term
costs associated with a cancer diagnosis for a household, has
to be prioritized.17 Fifty percent of cancer cases occur in high
SDI countries, but only 30% of cancer deaths, 25% of cancer
DALYs, and 23% of cancer YLLs. To ensure sustainable global
development, increased efforts are needed to reduce these
health inequalities. Recognizing the strong interdependen-
cies between socioeconomic status and health and the large
contribution of cancer to the overall disease burden is a first
step in making investments in cancer prevention and treat-
ment a priority.18 Cervical cancer is likely the best example of
inequalities in cancer with vast differences in burden by SDI.
As a completely preventable cancer where cost-effective
vaccination3 and screening approaches are available, cervi-
cal cancer has recently gained global attention through the
World Health Organization’s call for elimination.19 Falling in-
cidence rates in all SDI quintiles are encouraging, but coun-
tries with the least resources are still facing the largest bur-
den because of lack of screening programs. Immunization
against human papillomavirus, screening, and treatment of cer-
vical cancer is therefore of utmost importance in all socioeco-
nomic settings.
Deaths due to cancer contribute the majority of total health
loss measured in DALYs, with disability contributing less than
12% for all cancers. As access to cancer care increases and treat-
ments improve, cancer mortality decreases, but prevalence and
disability in the survivor population increase, which is al-
ready the case in some high-income countries.20 The World
Health Organization Global Action Plan for the Prevention and
Control of NCDs and the United Nations Sustainable Develop-
ment Goals focus on the reduction of premature mortality as
the first goal. At the same time, infrastructure should be
planned that can address the growing survivor population’s
need.
Limitations
The most important limitation for the GBD, as for other dis-
ease burden estimation, is the lack of data for many loca-
tions. A key GBD principle is to take advantage of all relevant
data sources. This means for cancer estimation that inci-
dence data from cancer registries, as well as mortality data from
vital registration systems or verbal autopsies, is used to pro-
duce disease burden estimates. Despite these broad inclu-
sion criteria for different types of data sources, certain loca-
tions have neither of these data sources available, and estimates
rely either on predictive covariates or trends from neighbor-
ing locations. Also, diagnostic accuracy for cause of death data
and ascertainment bias in cancer registries remains a limita-
tion, which requires corrections for underregistration and re-
distribution algorithms for insufficiently specific or implau-
sible diagnostic codes. Because of a lag in data availability,
estimates for the most recent years are based on past time
trends and covariates rather than data, which is reflected in
larger uncertainty. Scarcity of reliable survival data world-
wide requires the estimation of survival based on the mortality-
to-incidence ratio, which is a surrogate for survival. Because
in the majority of deaths due to Kaposi sarcoma the underly-
ing cause of deaths is AIDS, deaths and incidence of Kaposi sar-
coma are not estimated in the GBD. Also, common pediatric
cancers are not estimated separately in the GBD and are esti-
mated under the aggregated cause “other malignant neo-
plasms.”
Conclusions
The national epidemiological profiles of cancer burden in the
GBD study show large heterogeneities, which are a reflection
of different exposures to risk factors, economic settings, life-
styles, and access to care. The GBD study can be used by policy
makers and other stakeholders to develop and improve local
cancer control in order to achieve the global targets and im-
prove equity in cancer care.
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